Semaglutide Therapy for Kidney Protection in Type 2 Diabetes

Guideline-Based Recommendations

• The American Diabetes Association and Kidney Disease: Improving Global Outcomes (KDIGO) recommend using GLP-1 receptor agonists with proven cardiovascular benefit, such as semaglutide, in patients with type 2 diabetes and chronic kidney disease who do not meet glycemic targets with metformin and/or SGLT2 inhibitors, or who cannot use these drugs 1, 2
• The American College of Cardiology suggests that semaglutide should be considered as a first-line treatment alongside or instead of SGLT2 inhibitors for patients with type 2 diabetes and established cardiovascular disease or diabetic kidney disease 4, 5

Patient Selection and Monitoring

• The Kidney International guidelines recommend measuring eGFR and urinary albumin-to-creatinine ratio (UACR) before initiating semaglutide therapy, and monitoring kidney function regularly 1, 2
• The Journal of the American College of Cardiology suggests performing a dilated eye examination within 12 months if not done recently, particularly given the proliferative retinopathy signal seen with semaglutide in SUSTAIN-6 6, 4

Dosing and Administration

• The Mayo Clinic Proceedings state that no dose adjustment is required for semaglutide in patients with any level of kidney function, and recommend a standard initiation dose of 0.25 mg subcutaneously once weekly, titrated to 0.5 mg after 4 weeks, then to 1.0 mg after another 4 weeks as tolerated 3

Safety Considerations

• The Journal of the American College of Cardiology recommends using caution in patients with proliferative diabetic retinopathy based on SUSTAIN-6 findings, and considering alternative agents in patients with a history of pancreatitis 6, 4
• The American College of Cardiology suggests that semaglutide is contraindicated in patients with multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid cancer 6, 4